Kiniksa Pharmaceuticals, Ltd.
Price Action
Technical Summary
STAGE 2 UPTRENDKiniksa Pharmaceuticals, Ltd. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 145% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $52.98 | +17.81% | ABOVE |
| 50 SMA | $52.60 | +18.65% | ABOVE |
| 100 SMA | $49.29 | +26.61% | ABOVE |
| 150 SMA | $46.81 | +33.34% | ABOVE |
| 200 SMA | $44.67 | +39.73% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KNSA in an uptrend right now?
KNSA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KNSA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KNSA overbought or oversold?
KNSA's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is KNSA outperforming the market?
KNSA has a Relative Strength (RS) Rating of 88 out of 99. Yes, KNSA is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is KNSA in its 52-week range?
KNSA is trading at $62.41, which is 98% of its 52-week high ($63.77) and 96% above its 52-week low ($26.27).
How volatile is KNSA?
KNSA has a Beta of 0.18 and 52-week volatility of 44%. It's less volatile than the S&P 500 - generally more stable.